Cubist Pharmaceuticals
Top View
- 02/04/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:10:22 Report Id 2794D051 Page: 01
- Transactions in Chemicals & Pharmaceuticals
- 2794D051numericlist May 2015.Xlsx
- J&J Plans 10 Potential Blockbuster Filings by 2023
- Proxy Statement 2015 Annual Report Meet Eve
- Alliance Expertise at the Forefront: Leadership for the Ecosystem
- Cubist (NASDAQ:CBST) Company Report Please See the Disclaimer at Back of This Report for Important Information
- 20200915 MED-Project Participant List.Xlsx
- Drug Interactions
- Biostatus Winter // 2014
- 2016 Annual Report June 20, 2017 DEAR SHAREHOLDERS
- Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
- Jazz Pharmaceuticals
- Rebateable Manufacturers
- Manufacturer Abbreviations*
- Equity Research Report – Jazz Pharmaceuticals
- Schedule 14A Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No
- TC 1600 Iprs.Xlsx